Skip to main content
欧康医药 logo

欧康医药 — Investor Relations & Filings

Ticker · 920230 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 373 across all filing types
Latest filing 2023-04-12 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920230

About 欧康医药

https://www.okaypharm.com/

Oukang Pharmaceutical specializes in the research, development, and large-scale production of natural plant extracts, with a primary focus on citrus-derived flavonoids. The company’s core product portfolio includes high-purity ingredients such as Hesperidin, Diosmin, Methyl Hesperidin, and Neohesperidin Dihydrochalcone (NHDC). These products serve as essential raw materials for the global pharmaceutical, nutraceutical, food and beverage, and cosmetic sectors. Utilizing advanced extraction and purification technologies, the company maintains rigorous quality control standards to ensure compliance with international regulatory requirements. Its operations emphasize the industrialization of plant-based chemical derivatives to support diverse health and wellness applications.

Recent filings

Filing Released Lang Actions
成都欧康医药股份有限公司年度募集资金存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "年度募集资金存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It includes detailed information about the company's fundraising amount, usage, and balance for the year 2022. The report is prepared by management and verified by a registered accounting firm, indicating it is a specialized audit or assurance report on the use of raised capital. It references compliance with the Beijing Stock Exchange listing rules and includes financial figures related to fundraising and usage. This type of document is a standalone audit or verification report on fundraising usage, not a full annual report or earnings release. It is not a simple announcement or certification but a detailed verification report. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (9585 characters) supports it being a full report rather than a brief announcement.
2023-04-12 Chinese
关于调整募集资金投资项目拟投入募集资金及内部投资结构的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Chengdu Oukang Pharmaceutical Co., Ltd. regarding adjustments to the amount of funds raised to be invested in certain projects and the internal investment structure of those projects. It details the original and adjusted amounts of raised funds, reasons for the adjustments, approvals by the board of directors, supervisory board, independent directors, and the sponsoring institution. The document references regulatory approvals and compliance with securities regulations. It is not a full financial report, audit report, or earnings release, but rather a regulatory announcement about changes in the use of previously raised capital. The document length is 4151 characters, which is relatively short and focused on the announcement of adjustments rather than detailed financial data or comprehensive reporting. Therefore, it fits best under the category of Capital/Financing Update (CAP), as it concerns updates on the use and allocation of raised capital funds.
2023-04-12 Chinese
关于成都欧康医药股份有限公司非经营性资金占用及其他关联资金往来情况的专项审核说明
Audit Report / Information Classification · 95% confidence The document is a special audit report on non-operating fund occupation and other related party fund transactions for Chengdu Oukang Pharmaceutical Co., Ltd. It includes an auditor's statement, management responsibilities, and a detailed summary table of fund occupation and related party transactions for the year 2022. The document references an audit report with an unqualified opinion on the 2022 financial statements but is itself a standalone special audit review focused on specific financial aspects rather than the full annual report. It contains substantive financial data and audit opinions related to these specific transactions. Therefore, it fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. The document length (8129 characters) and content confirm it is a full report, not just an announcement or certification.
2023-04-12 Chinese
2022年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is a detailed announcement regarding the company's 2022 annual profit distribution plan (权益分派预案公告). It includes specifics about dividend distribution, board and supervisory committee approvals, independent director opinions, and references to company bylaws governing profit distribution. The document does not contain the full annual report or financial statements but focuses on the dividend proposal and related approvals. It is not a full Annual Report (10-K) or Earnings Release (ER), nor is it a simple announcement of report publication. The content aligns with a Notice of Dividend Amount (DIV) as it announces the dividend amount, payment basis, and related procedural details for shareholders.
2023-04-12 Chinese
拟续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the proposed reappointment of an accounting firm (audit firm) for the company's 2023 annual audit. It details the qualifications, independence, and audit fees of the accounting firm, as well as the board and independent directors' opinions on the reappointment. The document does not contain any actual audit report or financial statements but is a formal announcement about the audit firm appointment process and related approvals. The document length is 2890 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document fits best into the category of Audit Report / Information (AR), as it relates to audit information but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the audit firm and not the audit report results, it is more precisely an audit-related announcement. Given the definitions, the closest fit is AR (Audit Report / Information). FY 2023
2023-04-12 Chinese
独立董事关于第三届董事会第十七次会议相关事项的事前认可意见及独立意见
Board/Management Information Classification · 95% confidence The document is a detailed statement from independent directors providing pre-approval and independent opinions on various agenda items related to the company's 2022 annual work report, annual report, financial statements, profit distribution, auditor reappointment, budget, related party transactions, use of idle funds, fundraising adjustments, credit applications, and governance matters. It references the 2022 fiscal year and the upcoming 2022 annual general meeting for shareholder approval. The content is not the annual report itself but rather the independent directors' opinions on matters to be submitted to the annual shareholders meeting, which is typical for board/management information or governance-related disclosures. The document length is under 5,000 characters and does not contain full financial statements or detailed financial data, so it is not the annual report (10-K) or audit report (AR). It is not a voting result announcement (DVA) or proxy solicitation (PSI). The focus on board opinions and approvals aligns best with Board/Management Information (MANG).
2023-04-12 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.